RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for Pyxis Oncology (NASDAQ:PYXS) and maintained a price target of $7.
September 19, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Pyxis Oncology, maintaining a $7 price target, indicating confidence in the company's potential.
The reiteration of an Outperform rating and a maintained price target of $7 by RBC Capital suggests positive sentiment and confidence in Pyxis Oncology's future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100